IDH2 and acute myeloid leukemia: It could also efficaciously pass through the BBB and exert antitumor effects in glioma and AML animal models with IDH R132 mutations.484 Two open-label phase I trials of BAY-1436032 are ongoing to evaluate its PDs, safety, tolerability, and preliminary efficacy in patients with AML (NCT03127735) and solid tumors (NCT02746081), but the initial results have not been announced.